Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Prevalence of fibrodysplasia ossificans progressiva (FOP) in the United States: estimate from three treatment centers and a patient organization

Orphanet Journal of Rare Diseases(2021)10.1186/s13023-021-01983-2Source: DataRank Database

Prevalence of fibrodysplasia ossificans progressiva (FOP) in the United States: estimate from three treatment centers and a patient organization is a research paper published in Orphanet Journal of Rare Diseases (2021). On theSindex it has a DataRank of 0. It has been cited 65 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access65 citations

Download PDF

Cite:

Linked data & code

omim doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (9 grants)Impact (FWCI 7.91)OA: goldTopics (43)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (6)

Edward C. Hsiao ORCID,Geneviève Baujat ORCID,David Lapidus ORCID,Adam Sherman,Frederick S. Kaplan ORCID

Live enrichment

PubMed:34353327 PMC:PMC8340531 OpenAlex:https://openalex.org/W3189980870

National Institutes of Health

Grant: NIH R01AR073015

Mayo Clinic

Grant: Robert and Arlene Kogod Professorship

NIAMS NIH HHS

Grant: R01 AR073015

National Institutes of Health

Grant: 5R01AR073015-03

Pharmacologic modulation of innate immune dysfunction in heterotopic ossification

Radiant Hope Foundation

University of California, San Francisco

Ipsen Biopharmaceuticals

Regeneron Pharmaceuticals

Perelman School of Medicine, University of Pennsylvania

FWCI

7.91

Citation Percentile

1.0%

Citation Trend

2021

2022

2023

2024

2025

2026

goldLicense: cc-by

journalhttps://ojrd.biomedcentral.com/track/pdf/10.1186/s13023-021-01983-2

publisherhttps://ojrd.biomedcentral.com/track/pdf/10.1186/s13023-021-01983-2

publisherhttps://link.springer.com/content/pdf/10.1186/s13023-021-01983-2.pdf

publisherhttps://link.springer.com/article/10.1186/s13023-021-01983-2/fulltext.html

journalhttps://doi.org/10.1186/s13023-021-01983-2

Fields of Study

Heterotopic Ossification and Related ConditionsMedical Imaging and Pathology StudiesAquatic Invertebrate Ecology and Behavior0301 basic medicine0303 health sciences03 medical and health sciencesFemaleHumansMyositis OssificansOssification, HeterotopicPrevalenceRegistriesUnited States

MeSH Terms

FemaleHumansMyositis OssificansOssification, HeterotopicRegistriesUnited StatesPrevalence

Keywords

Fibrodysplasia ossificans progressivaMedicineHuman geneticsMyositis ossificansFamily medicinePediatricsPathologySurgeryGeneticsHeterotopic ossificationBiologyPrevalenceepidemiologyRare DiseaseAcvr1FopResearchOssification, HeterotopicRUnited StatesHumansFemaleRegistries

Sustainable Development Goals

SDG 3: 3. Good health